D'Souza C, Gupta A, Alldrick M D, Sastry B S
Department of Elderly Medicine, Rookwood Hospital, Fairwater Road, Llandaff, Cardiff CF5 2YN, UK.
Int J Clin Pract. 2003 May;57(4):295-300.
Psychosis is one of the most disabling complications associated with Parkinson's disease (PD) and occurs in up to 30% of PD patients treated chronically with antiparkinsonian drugs. Visual hallucinations, with or without delirium and paranoid delusions, are the most frequent symptoms. Psychosis complicating PD can be more disabling than the motor symptoms of PD; it frequently poses a serious threat to the patient's ability to maintain independence and is the single greatest risk factor for nursing home placement. Choosing an antipsychotic drug for a PD patient is a common clinical dilemma. The conventional antipsychotic drugs are poorly tolerated in PD because of their predictable and at times profound worsening in parkinsonian motor symptoms. The recent availability of atypical antipsychotic drugs that can control psychotic symptoms without compromising motor function has led to significant advances in therapeutic strategies in the management of PD psychosis in the community. This article reviews data on the use of atypical antipsychotics in patients with PD and the current recommendations on their use in the management of PD psychosis.
精神病是帕金森病(PD)最致残的并发症之一,在长期接受抗帕金森病药物治疗的PD患者中,发生率高达30%。视幻觉,无论有无谵妄和偏执妄想,都是最常见的症状。使PD复杂化的精神病可能比PD的运动症状更具致残性;它经常对患者维持独立的能力构成严重威胁,并且是入住养老院的单一最大风险因素。为PD患者选择抗精神病药物是一个常见的临床难题。传统抗精神病药物在PD患者中耐受性较差,因为它们可预见且有时会严重加重帕金森病的运动症状。近期可获得的能控制精神症状而不损害运动功能的非典型抗精神病药物,已在社区管理PD精神病的治疗策略方面取得了重大进展。本文综述了关于非典型抗精神病药物在PD患者中的使用数据以及目前关于其在管理PD精神病方面的使用建议。